Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Mo | After Kyowa Kirin buyout, Orchard scores FDA approval for first MLD gene therapy in the US | ||
Mo | Verastem, with FDA filing imminent, shows toll rare cancer takes on wellbeing | ||
Mo | Move over 'Greediad', GSK is now under alliterative fire from the AIDS Healthcare Foundation | ||
Mo | Bluebird bio secures loan lifeline from Hercules Capital to help support 3 gene therapy launches | ||
Mo | Pfizer set to collect roughly $2.6B in selloff of Haleon shares, reducing stake from 32% to 24% | ||
Mo | Following Boehringer's lead, AstraZeneca caps monthly out-of-pocket inhaler costs at $35 in the US | ||
Mo | AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remain | ||
Mo | Moderna embarks on new vax push in long COVID prevention campaign | ||
Mo | W.R. Grace debuts expanded operations at Michigan API facility | ||
Mo | BMS-backed radiopharma specialist Ratio expands manufacturing deal with CDMO PharmaLogic | ||
Fr | Novartis lays out $256M for antibody plant expansion in Singapore, plots 100 hires | ||
Fr | Despite early death concerns, FDA advisers back J&J and Legend's Carvykti for earlier myeloma | ||
Fr | Merck's Keytruda excels in cervical cancer trial, showing an ability to extend lives. Will a broader FDA approval follow? | ||
Fr | EuroAPI's troubles mount as audit reveals manufacturing lapses in Italy, spurring 2024 guidance suspension | ||
Fr | GLP-1s on track to take drug sales crown from PD-1 inhibitors in 2024: analyst | ||
Fr | Merck's Keytruda claims digital marketing crown, holding off challenges from AstraZeneca, BMS | ||
Fr | Fierce Pharma Asia-BIO-WuXi break-off; Takeda's site closure; FDA's concern over Carvykti | ||
Fr | With Pfizer struggling in 2023, CEO Bourla hit with 35% pay cut to $21.6M | ||
Do | Biocon continues to divest with $150M sale of insulin and other brands to Eris | ||
Do | NICE not sold on Vertex, CRISPR's groundbreaking sickle cell gene therapy Casgevy without more data | ||
Do | Charles River inks viral vector production pact for Navega's chronic pain gene therapy | ||
Do | AIDS advocates welcome 'greedy Gilead' to Miami with protests | ||
Mi | Aurobindo unit begins shipping drugs from India plant after FDA inspection triggered production halt | ||
Mi | Skincare products maker Galderma gears up for long-awaited $2.6B IPO | ||
Mi | J&J's Duato nets major raise to $28.4M, jumps to top of pharma CEO pay rankings |